Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Introducing the Srnt Oceania Chapter.

Gartner C, Waa AM, Walker N, Hao'uli S, Bonevski B.

Nicotine Tob Res. 2018 Jun 12. doi: 10.1093/ntr/nty118. [Epub ahead of print] No abstract available.

PMID:
29901773
2.

Are Australian smokers with mental illness receiving adequate smoking cessation and harm reduction information?

Sharma-Kumar R, Meurk C, Ford P, Beere D, Gartner C.

Int J Ment Health Nurs. 2018 May 2. doi: 10.1111/inm.12465. [Epub ahead of print]

PMID:
29718549
3.

Smoking behaviour and preferences for cessation support among clients of an Indigenous community-controlled health service.

Cockburn N, Gartner C, Ford PJ.

Drug Alcohol Rev. 2018 Jul;37(5):676-682. doi: 10.1111/dar.12691. Epub 2018 Mar 2.

PMID:
29498114
4.

Measuring spatial and temporal trends of nicotine and alcohol consumption in Australia using wastewater-based epidemiology.

Lai FY, Gartner C, Hall W, Carter S, O'Brien J, Tscharke BJ, Been F, Gerber C, White J, Thai P, Bruno R, Prichard J, Kirkbride KP, Mueller JF.

Addiction. 2018 Jun;113(6):1127-1136. doi: 10.1111/add.14157. Epub 2018 Feb 26.

PMID:
29333692
5.

How can we protect youth from putative vaping gateway effects without denying smokers a less harmful option?

Gartner C.

Addiction. 2018 Jan 11. doi: 10.1111/add.14126. [Epub ahead of print] No abstract available.

PMID:
29327489
6.

Cyclopentadienones via a tandem C-cyclopropylnitrone cyclization-cycloreversion sequence.

Erden I, Gärtner C, Ma J, Cabrera G, Markham K, Azimi S, Gronert S.

European J Org Chem. 2017 Sep 15;2017(34):5147-5153. doi: 10.1002/ejoc.201700915. Epub 2017 Sep 14.

PMID:
29200938
7.

Extending survival for people with hepatitis C using tobacco dependence treatment.

Gartner C, Miller A, Bonevski B.

Lancet. 2017 Nov 4;390(10107):2033. doi: 10.1016/S0140-6736(17)32460-1. No abstract available.

PMID:
29115237
8.

Smokers' understandings of addiction to nicotine and tobacco: A systematic review and interpretive synthesis of quantitative and qualitative research.

Pfeffer D, Wigginton B, Gartner C, Morphett K.

Nicotine Tob Res. 2017 Aug 29. doi: 10.1093/ntr/ntx186. [Epub ahead of print]

PMID:
29059355
9.

E-cigarettes and youth smoking: be alert but not alarmed.

Gartner CE.

Tob Control. 2018 Jul;27(4):359-360. doi: 10.1136/tobaccocontrol-2017-054002. Epub 2017 Sep 8. No abstract available.

PMID:
28887426
10.

An appraisal of practice guidelines for smoking cessation in people with severe mental illness.

Sharma R, Alla K, Pfeffer D, Meurk C, Ford P, Kisely S, Gartner C.

Aust N Z J Psychiatry. 2017 Nov;51(11):1106-1120. doi: 10.1177/0004867417726176. Epub 2017 Aug 31.

PMID:
28859486
11.

Is Virtual Surgical Planning in Orthognathic Surgery Faster Than Conventional Planning? A Time and Workflow Analysis of an Office-Based Workflow for Single- and Double-Jaw Surgery.

Steinhuber T, Brunold S, Gärtner C, Offermanns V, Ulmer H, Ploder O.

J Oral Maxillofac Surg. 2018 Feb;76(2):397-407. doi: 10.1016/j.joms.2017.07.162. Epub 2017 Jul 25.

PMID:
28826783
12.

No smoker left behind: it's time to tackle tobacco in Australian priority populations.

Bonevski B, Borland R, Paul CL, Richmond RL, Farrell M, Baker A, Gartner CE, Lawn S, Thomas DP, Walker N.

Med J Aust. 2017 Aug 21;207(4):141-142. No abstract available.

PMID:
28814207
13.

Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.

Bell S, Dean J, Gilks C, Boyd MA, Fitzgerald L, Mutch A, Baker P, Neilsen G, Gartner CE.

Int J Environ Res Public Health. 2017 Jul 18;14(7). pii: E799. doi: 10.3390/ijerph14070799.

14.

Do Neurobiological Understandings of Smoking Influence Quitting Self-Efficacy or Treatment Intentions?

Morphett K, Carter A, Hall W, Lucke J, Partridge B, Gartner C.

Nicotine Tob Res. 2018 Jun 7;20(7):827-835. doi: 10.1093/ntr/ntx144.

PMID:
28645199
15.

Should we encourage smokers with severe mental illness to switch to electronic cigarettes?

Sharma R, Gartner CE, Castle DJ, Mendelsohn CP.

Aust N Z J Psychiatry. 2017 Jul;51(7):663-664. doi: 10.1177/0004867417697823. Epub 2017 Mar 8. No abstract available.

PMID:
28633573
16.

Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners' attitudes.

Bell SK, Mena G, Dean J, Boyd M, Gilks C, Gartner C.

Drug Alcohol Depend. 2017 Aug 1;177:67-70. doi: 10.1016/j.drugalcdep.2017.03.023. Epub 2017 May 24.

PMID:
28577393
17.

Australian urban Indigenous smokers' perspectives on nicotine products and tobacco harm reduction.

Yuke K, Ford P, Foley W, Mutch A, Fitzgerald L, Gartner C.

Drug Alcohol Rev. 2018 Jan;37(1):87-96. doi: 10.1111/dar.12549. Epub 2017 May 10.

PMID:
28493405
18.

Framing Tobacco Dependence as a "Brain Disease": Implications for Policy and Practice.

Morphett K, Carter A, Hall W, Gartner C.

Nicotine Tob Res. 2017 Jul 1;19(7):774-780. doi: 10.1093/ntr/ntx006.

PMID:
28339586
19.

Blog fog? Using rapid response to advance science and promote debate.

O'Connor R, Gartner C, Henriksen L, Hill S, Barnoya J, Cohen J, Malone RE.

Tob Control. 2017 Mar;26(2):121. doi: 10.1136/tobaccocontrol-2017-053632. No abstract available.

PMID:
28220026
20.

Projecting the future smoking prevalence in Norway.

Gartner CE, Lund KE, Barendregt JJ, Mohamed Nor N, Hassan H, Vedøy TF, Kvaavik E.

Eur J Public Health. 2017 Feb 1;27(1):139-144. doi: 10.1093/eurpub/ckw180. No abstract available.

PMID:
28177432
21.

Australian mental health care practitioners' practices and attitudes for encouraging smoking cessation and tobacco harm reduction in smokers with severe mental illness.

Sharma R, Meurk C, Bell S, Ford P, Gartner C.

Int J Ment Health Nurs. 2018 Feb;27(1):247-257. doi: 10.1111/inm.12314. Epub 2017 Feb 3.

PMID:
28160384
22.

Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study.

Gerhardt F, Dumitrescu D, Gärtner C, Beccard R, Viethen T, Kramer T, Baldus S, Hellmich M, Schönau E, Rosenkranz S.

Heart. 2017 Apr;103(8):592-598. doi: 10.1136/heartjnl-2016-309852. Epub 2017 Jan 18.

23.

Microfluidics-Enabled Diagnostic Systems: Markets, Challenges, and Examples.

Becker H, Gärtner C.

Methods Mol Biol. 2017;1547:3-21. doi: 10.1007/978-1-4939-6734-6_1. Review.

PMID:
28044283
24.

Motivations and Limitations Associated with Vaping among People with Mental Illness: A Qualitative Analysis of Reddit Discussions.

Sharma R, Wigginton B, Meurk C, Ford P, Gartner CE.

Int J Environ Res Public Health. 2016 Dec 22;14(1). pii: E7. doi: 10.3390/ijerph14010007.

25.

Medicalisation, smoking and e-cigarettes: evidence and implications.

Morphett K, Carter A, Hall W, Gartner C.

Tob Control. 2017 Dec;26(e2):e134-e139. doi: 10.1136/tobaccocontrol-2016-053348. Epub 2016 Nov 30.

PMID:
27903957
26.

Views and Preferences for Nicotine Products as an Alternative to Smoking: A Focus Group Study of People Living with Mental Disorders.

Meurk C, Ford P, Sharma R, Fitzgerald L, Gartner C.

Int J Environ Res Public Health. 2016 Nov 23;13(11). pii: E1166.

27.

Is It Safe to Vape? Analyzing Online Forums Discussing E-Cigarette Use during Pregnancy.

Wigginton B, Gartner C, Rowlands IJ.

Womens Health Issues. 2017 Jan - Feb;27(1):93-99. doi: 10.1016/j.whi.2016.09.008. Epub 2016 Oct 20.

PMID:
27773530
28.

The challenge of reducing smoking in people with serious mental illness.

Sharma R, Gartner CE, Hall WD.

Lancet Respir Med. 2016 Oct;4(10):835-844. doi: 10.1016/S2213-2600(16)30228-4. Review.

PMID:
27707462
29.

Evaluation of a microfluidic chip system for preparation of bacterial DNA from swabs, air, and surface water samples.

Julich S, Hotzel H, Gärtner C, Trouchet D, Fawzy El Metwaly Ahmed M, Kemper N, Tomaso H.

Biologicals. 2016 Nov;44(6):574-580. doi: 10.1016/j.biologicals.2016.06.013. Epub 2016 Aug 9.

30.

An integrative microfluidically supported in vitro model of an endothelial barrier combined with cortical spheroids simulates effects of neuroinflammation in neocortex development.

Raasch M, Rennert K, Jahn T, Gärtner C, Schönfelder G, Huber O, Seiler AE, Mosig AS.

Biomicrofluidics. 2016 Jul 5;10(4):044102. doi: 10.1063/1.4955184. eCollection 2016 Jul.

31.

Cocaine, MDMA and methamphetamine residues in wastewater: Consumption trends (2009-2015) in South East Queensland, Australia.

Lai FY, O'Brien JW, Thai PK, Hall W, Chan G, Bruno R, Ort C, Prichard J, Carter S, Anuj S, Kirkbride KP, Gartner C, Humphries M, Mueller JF.

Sci Total Environ. 2016 Oct 15;568:803-809. doi: 10.1016/j.scitotenv.2016.05.181. Epub 2016 Jun 17.

PMID:
27325011
32.

Spatial variations in the consumption of illicit stimulant drugs across Australia: A nationwide application of wastewater-based epidemiology.

Lai FY, O'Brien J, Bruno R, Hall W, Prichard J, Kirkbride P, Gartner C, Thai P, Carter S, Lloyd B, Burns L, Mueller J.

Sci Total Environ. 2016 Oct 15;568:810-818. doi: 10.1016/j.scitotenv.2016.05.207. Epub 2016 Jun 3.

PMID:
27267725
33.

The potential impact of vaporized nicotine products on vulnerable subpopulations.

Gartner C.

Addiction. 2017 Jan;112(1):18-19. doi: 10.1111/add.13404. Epub 2016 May 6. No abstract available.

PMID:
27154404
34.

Rethinking therapeutic and recreational nicotine products: a commentary on Hatsukami et al.

Borland R, Gartner C.

Tob Control. 2016 May;25(3):245. doi: 10.1136/tobaccocontrol-2015-052388. No abstract available.

PMID:
27103635
35.

Assessing the place of nicotine vaporisers in tobacco control.

Gartner C, Hall W.

Tob Control. 2016 Apr;25(e1):e1-2. doi: 10.1136/tobaccocontrol-2016-053025. No abstract available.

PMID:
27033365
36.

A qualitative study of smokers' views on brain-based explanations of tobacco dependence.

Morphett K, Carter A, Hall W, Gartner C.

Int J Drug Policy. 2016 Mar;29:41-8. doi: 10.1016/j.drugpo.2015.12.011. Epub 2015 Dec 19.

PMID:
26821556
37.

Describing the role of Australian community pharmacists in oral healthcare.

Taing MW, Ford PJ, Gartner CE, Freeman CR.

Int J Pharm Pract. 2016 Aug;24(4):237-46. doi: 10.1111/ijpp.12241. Epub 2016 Jan 25.

PMID:
26809378
38.

THE RESULTS OF THE EURADOS INTERCOMPARISON IC2014 FOR WHOLE-BODY DOSEMETERS IN PHOTON FIELDS.

Stadtmann H, Grimbergen TW, Figel M, Romero AM, McWhan AF, Gärtner C.

Radiat Prot Dosimetry. 2016 Sep;170(1-4):86-9. doi: 10.1093/rpd/ncv522. Epub 2016 Jan 12.

PMID:
26763903
39.

YouTube as a source of quit smoking information for people living with mental illness.

Sharma R, Lucas M, Ford P, Meurk C, Gartner CE.

Tob Control. 2016 Nov;25(6):634-637. doi: 10.1136/tobaccocontrol-2015-052713. Epub 2016 Jan 12.

PMID:
26758030
40.

Assessing the effectiveness of High Intensity Interval Training (HIIT) for smoking cessation in women: HIIT to quit study protocol.

Pavey TG, Gartner CE, Coombes JS, Brown WJ.

BMC Public Health. 2015 Dec 29;15:1309. doi: 10.1186/s12889-015-2631-3.

41.

[Risc factors for assisted suicide for cancer patients - mental burden of bereaved].

Gärtner C, Müller-Busch HC.

Wien Med Wochenschr. 2015 Dec;165(23-24):482-6. doi: 10.1007/s10354-015-0404-3. Epub 2015 Nov 30. German.

PMID:
26620467
42.

Stuck in the catch 22: attitudes towards smoking cessation among populations vulnerable to social disadvantage.

Pateman K, Ford P, Fizgerald L, Mutch A, Yuke K, Bonevski B, Gartner C.

Addiction. 2016 Jun;111(6):1048-56. doi: 10.1111/add.13253. Epub 2016 Jan 5.

PMID:
26615055
43.

[Imitation of an Anderson type II dens fracture by a motion artefact in computed tomography : Four case examples].

Morgenstern M, Friederichs J, Gärtner C, Bühren V, Gonschorek O.

Unfallchirurg. 2016 May;119(5):450-3. doi: 10.1007/s00113-015-0112-x. German.

PMID:
26537970
44.

Mull it over: cannabis vaporizers and harm reduction.

Gartner CE.

Addiction. 2015 Nov;110(11):1709-10. doi: 10.1111/add.13139.

PMID:
26471154
45.

Protocol for a randomised pragmatic policy trial of nicotine products for quitting or long-term substitution in smokers.

Fraser D, Borland R, Gartner C.

BMC Public Health. 2015 Oct 6;15:1026. doi: 10.1186/s12889-015-2366-1.

46.

Electronic Cigarettes: Awareness, Recent Use, and Attitudes Within a Sample of Socioeconomically Disadvantaged Australian Smokers.

Twyman L, Bonevski B, Paul C, Bryant J, Gartner C, Guillaumier A.

Nicotine Tob Res. 2016 May;18(5):670-7. doi: 10.1093/ntr/ntv183. Epub 2015 Sep 16.

PMID:
26377518
47.

Tobacco harm reduction in people with serious mental illnesses.

Gartner C, Hall W.

Lancet Psychiatry. 2015 Jun;2(6):485-7. doi: 10.1016/S2215-0366(15)00238-2. Epub 2015 May 27. No abstract available.

PMID:
26360430
48.

Sex specific impact of prodromal chest pain on pre-hospital delay time during an acute myocardial infarction: Findings from the multicenter MEDEA Study with 619 STEMI patients.

von Eisenhart Rothe AF, Albarqouni L, Gärtner C, Walz L, Smenes K, Ladwig KH.

Int J Cardiol. 2015 Dec 15;201:581-6. doi: 10.1016/j.ijcard.2015.01.067. Epub 2015 Jan 27.

PMID:
26334383
49.

A microfluidically perfused three dimensional human liver model.

Rennert K, Steinborn S, Gröger M, Ungerböck B, Jank AM, Ehgartner J, Nietzsche S, Dinger J, Kiehntopf M, Funke H, Peters FT, Lupp A, Gärtner C, Mayr T, Bauer M, Huber O, Mosig AS.

Biomaterials. 2015 Dec;71:119-131. doi: 10.1016/j.biomaterials.2015.08.043. Epub 2015 Aug 25.

PMID:
26322723
50.

E-cigarettes and the law in Australia.

Douglas H, Hall W, Gartner C.

Aust Fam Physician. 2015 Jun;44(6):415-8.

Supplemental Content

Loading ...
Support Center